$NTRA

Brophy Michael Burkes sold $1.3M of NTRA

Brophy Michael Burkes (CHIEF FINANCIAL OFFICER) sold 5,064 shares of Natera, Inc. (NTRA) at an average of $253.28 ($249.38–$260.49, $1.28M total) across 5 trades over 2026-07-27 to 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brophy Michael Burkes
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The only new information is the disclosed sale size, timing, and 10b5-1 status; it does not introduce new fundamentals.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a fundamental repricing by itself.

03

What to watch

The article does not provide context on total insider holdings, option exercises, or whether other insiders sold/bought around the same window.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29 for sales executed 2026-07-27 to 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CFO Brophy Michael Burkes sold about $1.28M of NTRA shares via an open-market sale under a 10b5-1 plan (Form 4).

Expected impact

Likely limited near-term impact; any effect is typically sentiment-only unless paired with other new fundamentals.

Evidence & confidence

The filing is a routine Form 4 open-market sale by the CFO, explicitly under a pre-arranged 10b5-1 plan, with no new guidance, deal, or regulatory action disclosed.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Because the trades were executed under a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose CFO filed the Form 4 insider sale disclosure.

  • Brophy Michael Burkes

    Natera CFO who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.